⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27496274 | 0.95 | — | — | |
| SCHEMBL8994354 | 0.93 | — | — | |
| SCHEMBL5898104 | 0.93 | — | — | |
| SCHEMBL8393191 | 0.93 | CES2 (0.33) | — | |
| SCHEMBL9335673 | 0.91 | — | — | |
| SCHEMBL27498248 | 0.91 | CES2 (0.34) | — | |
| SCHEMBL8895789 | 0.85 | TSHR (0.37) | — | |
| SCHEMBL5070254 | 0.85 | TSHR (0.35) | — | |
| SCHEMBL18600102 | 0.85 | TSHR (0.35) | — | |
| SCHEMBL27882653 | 0.84 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6222025-B1 | OLIGONUCLEOTIDES HAVING 2' AND 5 SUBSTITUTED PYRIMIDINE NUCLEOTIDES; INCREASED AFFINITY FOR NUCLEIC ACIDS; INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | claimed |
| US-11781144-B2 | Inhibition of oxidative stress in atrial fibrillation | NORTHWESTERN UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230122801-A1 | USP10 TARGETED SELF-DELIVERABLE SIRNA COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING FIBROSIS AND/OR SCARRING | UNIV NEW YORK STATE RES FOUND (US) | 2023-04-20 | — | — | US | disclosed |
| US-10988767-B2 | Inhibition of oxidative stress in atrial fibrillation | NORTHWESTERN UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| EP-2454371-B1 | CHEMICAL MODIFICATION OF SMALL HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION | SOMAGENICS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10870850-B2 | Chemical modification of short small hairpin RNAs for inhibition of gene expression | SOMAGENICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190032058-A1 | INHIBITION OF OXIDATIVE STRESS IN ATRIAL FIBRILLATION | NORTHWESTERN UNIVERSITY | 2019-01-31 | — | — | US | disclosed |
| US-10023866-B2 | Compositions and methods for inhibition of nucleic acids function | Life Technologies Corporation (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180148723-A1 | CHEMICAL MODIFICATION OF SHORT SMALL HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION | SOMAGENICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9932588-B2 | Inhibition of oxidative stress in atrial fibrillation | NORTHWESTERN UNIVERSITY (US) | 2018-04-03 | — | — | US | disclosed |
| US-5519134-A | ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-21 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995023160-A1 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995018623-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018792-A1 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |